Business Context and Reporting Period
Company: X4 Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2025
Event: Entry into a Material Definitive Agreement (Equity Line of Credit) with Lincoln Park Capital Fund, LLC.
Key Financial Metrics and Transaction Terms
This filing details a structured equity financing arrangement rather than reporting period-end financial results (revenue, profit, or cash flow).
- Aggregate Offering Size: Up to $40,000,000 in Common Stock.
- Term: 24 months from June 23, 2025.
- Commitment Fee: Issuance of 137,099 shares of Common Stock (no cash proceeds).
- Outstanding Shares (Pre-Issuance): 7,178,764 shares.
- Exchange Cap: Limited to 19.99% of outstanding shares (approx. 1,435,035 shares) unless shareholder approval is obtained or the average sale price exceeds $2.67 per share.
- Beneficial Ownership Cap: Lincoln Park limited to 4.99% (expandable to 9.99% with notice).
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Transaction Mechanics
The Company has established a flexible mechanism to sell shares at its discretion, subject to price and volume thresholds:
- Regular Purchases: Company may direct sales of up to 30,000 shares daily if the closing price is $\ge$ $0.50. Limits increase to 35,000, 40,000, 50,000, or 60,000 shares if the closing price reaches $3.50, $4.00, $4.50, or $5.00, respectively. Maximum single purchase obligation is $500,000 unless mutually agreed otherwise.
- Pricing Formula: 97% of the lesser of the lowest sale price on the date of sale or the average of the three lowest closing prices during the preceding 10 business days.
- Accelerated Purchases: Company may direct additional purchases up to 300% of the Regular Purchase amount or 30% of trading volume, subject to specific measurement periods.
- Restrictions: Lincoln Park is prohibited from short selling or hedging the Common Stock. The Company cannot enter into other equity lines of credit during the term, excluding "at the market" offerings.
Guidance, Outlook, and Risks
Management Commentary: The Company expects to use proceeds for working capital. Actual proceeds depend on market conditions, trading price, and the Company's funding determinations. The Company retains the right to terminate the agreement at any time without penalty.
Risks and Contingencies:
- Dilution: Issuance of shares up to the Exchange Cap or beyond (if approved) will dilute existing shareholders.
- Market Conditions: Sales are contingent on the stock price not falling below $0.50 for Regular Purchases.
- Forward-Looking Statements: Results may differ due to market uncertainties and clinical trial outcomes (referenced in 10-K and 10-Q filings).
Investor Verification Checklist
- Verify the current trading price of XFOR on Nasdaq to assess the likelihood of triggering Regular Purchase thresholds ($0.50 minimum).
- Review the Company's most recent 10-Q (ended March 31, 2025) and 10-K (ended December 31, 2024) for cash runway and liquidity needs.
- Monitor for shareholder vote announcements if the Company intends to exceed the 19.99% Exchange Cap without meeting the $2.67 average price exemption.
- Check subsequent filings for actual share issuances and the total commitment fee impact on share count.